Prothena to Participate in the J.P. Morgan Healthcare Conference
January 04 2017 - 4:05PM
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company focused on the discovery, development and
commercialization of novel protein immunotherapies, today announced
that members of its senior management team will present and
participate in the 35th Annual J.P. Morgan Healthcare Conference on
January 12th at 11:00 AM PT in San Francisco, CA.
A live webcast of the company presentation can
be accessed through the investor relations section of the Company's
website at www.prothena.com. Following the live presentation, a
replay of the webcast will be available on the Company's website
for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a global, late-stage
clinical biotechnology company seeking to fundamentally change the
course of progressive diseases with its clinical pipeline of novel
therapeutic antibodies. Fueled by its deep scientific understanding
built over decades of research in protein misfolding and cell
adhesion — the root causes of many serious or currently untreatable
amyloid and inflammatory diseases — Prothena is establishing a
fully integrated research, development and commercial focus and has
advanced several drug candidates into clinical studies while
pursuing discovery of additional novel therapies. Our pipeline of
antibody-based product candidates targets a number of potential
indications including AL amyloidosis (NEOD001), Parkinson's disease
and other related synucleinopathies (PRX002), inflammatory
diseases, including psoriasis and psoriatic arthritis (PRX003), and
ATTR amyloidosis (PRX004). For more information, please visit the
company's website at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com
Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Apr 2023 to Apr 2024